[Newsmp] The Ministry of Food and Drug Safety authorized the use of the orphan medication 'Minjuvi (Tafasitamab)' for the treatment of diffuse large B-cell lymphoma on 9 June.
Diffuse large B-cell lymphoma is the most common lymphoma, known for its fast progression.
In the treatment of diffuse large B-cell lymphoma in adults, Minjuvi is used first in combination with lenalidomide and later its own.
And it is specifically intended for individuals whose cancer has returned or shown resistance to previous treatments and who are not eligible for autologous stem cell transplantation.
This medication provides new treatment opportunities for diffuse large B-cell lymphoma by attaching to the CD19 protein on B-cell surfaces, leading to direct cell death, antibody-dependent cellular phagocytosis, and antibody-dependent cellular cytotoxicity, resulting in B-cell depletion.
The Ministry of Food and Drug Safety described Minjuvi as a humanized CD19-specific monoclonal antibody of the immunoglobulin G (IgG), a cell surface antigen protein on B-lymphocytes.
